<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02055066</url>
  </required_header>
  <id_info>
    <org_study_id>ARGX-111-1301</org_study_id>
    <nct_id>NCT02055066</nct_id>
  </id_info>
  <brief_title>A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.</brief_title>
  <official_title>A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer Over-expressing the c-Met Protein.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>argenx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>argenx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a first-in-human study of an antibody blocking the function of the oncogene c-met in&#xD;
      patients with cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 1b trial will characterize the safety profile of ARGX 111 and will thus provide&#xD;
      the first elements towards establishing an accurate risk-benefit assessment for ARGX 111 in&#xD;
      cancer patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity</measure>
    <time_frame>1 month</time_frame>
    <description>Number of patients with grade 3 or 4 toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profiles (Cmax , Ctrough, AUC, Vd , clearance, and half-life)</measure>
    <time_frame>C1 D1 (pre, 0h, 2h, 6h, 12h, 24h), C1D8, C1D15; Cycle ≥2 o D1 pre-/post-dose</time_frame>
    <description>Measurement of drug concentration in the blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers (Hepatocyte growth factor; ADCC)</measure>
    <time_frame>Base-line and pre-dose at each cycle for an average of 4 months</time_frame>
    <description>measurements of cytokine changes in blood as a result of drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events per dose level</measure>
    <time_frame>for an average of 4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARGX-111 0.3 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARGX-111 1.0 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARGX-111 3.0 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARGX-111 10 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARGX-111</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent.&#xD;
&#xD;
          2. Age ≥ 18 years.&#xD;
&#xD;
          3. Performance status of 0 or 1.&#xD;
&#xD;
          4. Histological diagnosis of malignancy.&#xD;
&#xD;
          5. Cancer relapsing after, or refractory to standard therapy.&#xD;
&#xD;
          6. Malignancy over-expressing the c Met protein.&#xD;
&#xD;
          7. Presence of circulating tumor cells (CTCs).&#xD;
&#xD;
          8. At least one tumor lesion &gt; 2 cm on PET/CT.&#xD;
&#xD;
          9. Serum albumin &gt; 35 g/L.&#xD;
&#xD;
         10. Absolute neutrophil count (ANC) &gt; 1.0 x 109/L.&#xD;
&#xD;
         11. Hemoglobin &gt; 90 g/L (0.9 g/dL).&#xD;
&#xD;
         12. Platelet count ≥ 75 x 109/L.&#xD;
&#xD;
         13. Coagulation parameters ≤ 1.5 x ULN.&#xD;
&#xD;
         14. Total bilirubin ≤ 1.5 x upper limit of normal (ULN).&#xD;
&#xD;
         15. Creatine Phosphokinase (CPK) ≤ 2.5 x ULN.&#xD;
&#xD;
         16. Serum creatinine ≤ 1.5 x ULN.&#xD;
&#xD;
         17. Ability to comply with protocol-specified procedures/evaluations and scheduled visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or clinical evidence of neoplastic central nervous system (CNS) involvement.&#xD;
&#xD;
          2. Major surgery within 4 weeks of ARGX 111 first dose administration.&#xD;
&#xD;
          3. Systemic glucocorticoid administration at doses greater than physiological replacement&#xD;
             (prednisone 20 mg equivalent) within 3 weeks of ARGX 111 first dose administration.&#xD;
&#xD;
          4. Cytotoxic chemotherapy within 3 weeks of ARGX 111 first dose administration.&#xD;
&#xD;
          5. Radiation therapy with curative intent within 3 weeks of ARGX 111 first dose&#xD;
             administration.&#xD;
&#xD;
          6. Biological therapy (monoclonal antibodies) within 4 weeks of ARGX 111 first dose&#xD;
             administration.&#xD;
&#xD;
          7. Biological therapy (other than monoclonal antibodies) within 5 half-lives of ARGX 111&#xD;
             first dose administration.&#xD;
&#xD;
          8. Unresolved Grade 3 or 4 toxicity from prior therapy, including experimental therapy.&#xD;
&#xD;
          9. History of recurrent Grade 3 or 4 toxicity from anti c Met therapy.&#xD;
&#xD;
         10. Uncontrolled diabetes, defined as fasting glycemia &gt; 150 mg/dl).&#xD;
&#xD;
         11. Active, untreated viral, bacterial, or systemic fungal infection.&#xD;
&#xD;
         12. Any clinical finding, including psychiatric and behavioral problems, which, in the&#xD;
             opinion of the Investigator, precludes the patient from safely participating in the&#xD;
             study.&#xD;
&#xD;
         13. Childbearing potential (unless using an adequate measure of contraception).&#xD;
&#xD;
         14. Pregnancy or lactation.&#xD;
&#xD;
         15. History of severe (Grade 3 or 4) hypersensitivity to recombinant proteins.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmad Awada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jules Bordet Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitair Zieckenhuis Antwerpen</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>January 31, 2014</study_first_submitted>
  <study_first_submitted_qc>February 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2014</study_first_posted>
  <last_update_submitted>April 20, 2017</last_update_submitted>
  <last_update_submitted_qc>April 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>c-MET</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

